Beta-carotene, vitamin C, and vitamin E and cardiovascular diseases

[1]  T. Lakka,et al.  The effect of vitamin E and vitamin C on 3-year progression of carotid atherosclerosis: The antioxidant supplementation in atherosclerosis prevention (ASAP) study , 2000 .

[2]  S. Yusuf,et al.  Vitamin E supplementation and cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.

[3]  D. Albanes,et al.  Controlled Trial of α-Tocopherol and β-Carotene Supplements on Stroke Incidence and Mortality in Male Smokers , 2000 .

[4]  D. Albanes,et al.  The effect of alpha-tocopherol and beta-carotene supplementation on symptoms and progression of intermittent claudication in a controlled trial. , 1999, Atherosclerosis.

[5]  GISSI-Prevenzione Investigators,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial , 1999, The Lancet.

[6]  R. Brigelius-Flohé,et al.  Vitamin E: function and metabolism , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  J. Freedman,et al.  Vitamin E and vascular homeostasis: implications for atherosclerosis , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  J. B. Park,et al.  Criteria and recommendations for vitamin C intake. , 1999, JAMA.

[9]  D. Tribble.  Antioxidant Consumption and Risk of Coronary Heart Disease: Emphasis on Vitamin C, Vitamin E, and β-Carotene A Statement for Healthcare Professionals From the American Heart Association , 1999 .

[10]  A. Hofman,et al.  Dietary antioxidants and risk of myocardial infarction in the elderly: the Rotterdam Study. , 1999, The American journal of clinical nutrition.

[11]  R. Collins,et al.  MRC BHFHeart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience , 1999 .

[12]  M. Keltai,et al.  Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). , 1999, European heart journal.

[13]  J. Welch.  MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. , 1999, European heart journal.

[14]  P Galan,et al.  A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population: the SU.VI.MAX study--design, methods, and participant characteristics. SUpplementation en VItamines et Minéraux AntioXydants. , 1998, Controlled clinical trials.

[15]  P Galan,et al.  The potential role of antioxidant vitamins in preventing cardiovascular diseases and cancers. , 1998, Nutrition.

[16]  S. Ripatti,et al.  Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. , 1998, Archives of internal medicine.

[17]  D. Albanes,et al.  Effect of alpha-tocopherol (vitamin E) and beta-carotene supplementation on the incidence of intermittent claudication in male smokers. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[18]  S. Yusuf,et al.  Is there a role for antioxidant vitamins in the prevention of cardiovascular diseases? An update on epidemiological and clinical trials data. , 1997, The Canadian journal of cardiology.

[19]  J. Keaney,et al.  Antioxidants and atherosclerotic heart disease. , 1997, The New England journal of medicine.

[20]  S. Ripatti,et al.  Randomised trial of α-tocopherol and β-carotene supplements on incidence of major coronary events in men with previous myocardial infarction , 1997, The Lancet.

[21]  J. Salonen,et al.  First myocardial infarction in patients of Indian subcontinent and European origin: comparison of risk factors, management, and long term outcome , 1997, BMJ.

[22]  T. Harris,et al.  Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the Established Populations for Epidemiologic Studies of the Elderly. , 1996, The American journal of clinical nutrition.

[23]  J. Manson,et al.  Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. , 1996, The New England journal of medicine.

[24]  G. Omenn,et al.  Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. , 1996, The New England journal of medicine.

[25]  A. Folsom,et al.  Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. , 1996, The New England journal of medicine.

[26]  F. Kelly,et al.  Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) , 1996, The Lancet.

[27]  M. Karagas,et al.  Mortality associated with low plasma concentration of beta carotene and the effect of oral supplementation , 1996 .

[28]  J. Manson,et al.  Antioxidant vitamin-cardiovascular disease hypothesis is still promising, but still unproven: the need for randomized trials. , 1995, The American journal of clinical nutrition.

[29]  E. Niki,et al.  Action of beta-carotene as an antioxidant against lipid peroxidation. , 1995, Archives of biochemistry and biophysics.

[30]  D. Steinberg.  Clinical trials of antioxidants in atherosclerosis: are we doing the right thing? , 1995, The Lancet.

[31]  G A Colditz,et al.  A prospective study of consumption of carotenoids in fruits and vegetables and decreased cardiovascular mortality in the elderly. , 1995, Annals of epidemiology.

[32]  D. L. Morris,et al.  Serum carotenoids and coronary heart disease. The Lipid Research Clinics Coronary Primary Prevention Trial and Follow-up Study. , 1994, JAMA.

[33]  A. Reunanen,et al.  Antioxidant vitamin intake and coronary mortality in a longitudinal population study. , 1994, American journal of epidemiology.

[34]  D. Albanes,et al.  The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. , 1994, The New England journal of medicine.

[35]  M. Gail,et al.  Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. , 1993, Journal of the National Cancer Institute.

[36]  J. Manson,et al.  Vitamin E consumption and the risk of coronary disease in women. , 1993, The New England journal of medicine.

[37]  E. Rimm,et al.  Vitamin E consumption and the risk of coronary heart disease in men. , 1993, The New England journal of medicine.

[38]  H. Stähelin,et al.  Increased risk of cardiovascular disease at suboptimal plasma concentrations of essential antioxidants: an epidemiological update with special attention to carotene and vitamin C. , 1993, The American journal of clinical nutrition.

[39]  P. Reaven,et al.  Effect of dietary antioxidant combinations in humans. Protection of LDL by vitamin E but not by beta-carotene. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[40]  J. Enstrom,et al.  Vitamin C Intake and Mortality among a Sample of the United States Population , 1992, Epidemiology.

[41]  F. Kok,et al.  Supplementation with vitamin E but not beta-carotene in vivo protects low density lipoprotein from lipid peroxidation in vitro. Effect of cigarette smoking. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[42]  Verlangieri Aj,et al.  Effects of d-alpha-tocopherol supplementation on experimentally induced primate atherosclerosis. , 1992 .

[43]  S. Grundy,et al.  β-Carotene inhibits the oxidative modification of low-density lipoprotein , 1991 .

[44]  L. Fong,et al.  High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. , 1990, Biochimica et biophysica acta.

[45]  J L Witztum,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.

[46]  J. Steinberg.  Book ReviewAmbulatory Pediatric Care , 1989 .

[47]  T. Carew,et al.  Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. , 1987, Proceedings of the National Academy of Sciences of the United States of America.